Condition: Opioid-use Disorder · Sponsor: New York State Psychiatric Institute
This study will evaluate the effectiveness of a new pharmacological approach to increase efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with opioid use disorder by combining it with buprenorphine-naloxone. This is a two arm, double-blind, placebo-controlled study to examine whether addition of buprenorphine-naloxone will improve treatment retention, reduce opioid craving, and improve mood over 24 weeks of treatment with extended release naltrexone (XR-naltrexone) administered every four weeks for a total of 6 injections.
This description comes directly from the study's public registry record.
Adam Bisaga, MD · 646-774-6155 · amb107@columbia.edu
Onumara Opara, MPH · onumara.opara@nyspi.columbia.edu
Always discuss trial participation with your own doctor first.
| Avery Road Treatment Center (ARTC) | Rockville, Maryland, United States | Recruiting |
| Stars/Nyspi | New York, New York, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05011266